Journal: Journal of Translational Autoimmunity

Article Title: Anti-IgLON5 encephalitis is associated with anti-retinal immunological reactivity without retinal alteration

doi: 10.1016/j.jtauto.2026.100359

Figure Lengend Snippet: Indirect immunofluorescence on sections of monkey retina. The fluorescence observed is identified by a black arrow. (A) Patient 4 (IgG4); (B) Patient 1 (IgG4); (C) Patient 3 (IgG1); (D) Patient 5 (IgG4); (E) Patient 2 (IgG1); (F) Patient 1 (IgG4) after immunoadsorption of IgLON5 antibodies; (G) Control with macular edema (IgG1); (H) Control with anti-Hu encephalitis (IgG1); (I) Control with CAR syndrome (IgG4). The different layers of the retina are identified by their initials: pigment epithelium (pe), photoreceptor layer (pr), outer grain layer (og), outer plexiform layer (op), inner grain layer (ig), inner plexiform layer (ip), ganglion cell layer (gc), nerve fibre layer (nf).

Article Snippet: The reactivity of the patients’ sera and/or CSF against the retina was evaluated retrospectively with frozen samples (−80°, EXPLAINEUR biobank) through an indirect immunofluorescence technique using sections of monkey retina (Ref. FA1172-1005, Euroimmun), detected with an FITC-labelled secondary antibody anti-human IgAGM (Euroimmun conjugate) or directed against IgA (ref. F0204, DAKO), IgM (ref. F0203, DAKO), IgG1 (ref. 9052-02, Southern Biotech) and IgG4 (ref. 9200-02, Southern Biotech).

Techniques: Immunofluorescence, Fluorescence, Control

Journal: bioRxiv

Article Title: Combination antagonism of TNF superfamily signaling for T cell immunosuppression

doi: 10.64898/2026.04.27.721101

Figure Lengend Snippet: ( A ) Interleukin-2 (IL-2) and interferon gamma (IFN-γ) inhibition in CD3 + cells during allogeneic one-way MLR measured at day 2 and day 5, respectively, treated with 50 nM combination pharmacological inhibitors of TNF/TNFR targets of interest. Monotreatment groups included 50 nM of human IgG1. Cytokine inhibition was calculated as percent reduction from IgG1 control treatment. Ill denotes P <0.05 in student t-test for monotreatments vs. IgG1 control, # denotes P <0.05 in student t-tests for combination treatment groups vs. IgG1 controls and both constituent monotreatments. ( B ) Normalized IL-2 and IFN-γ expression in four promising combinations of TNF/TNFR inhibitors. ( C-D ) Proliferation in CD3 + cells during allogeneic one-way MLR measured at day 5 in the presence of combination pharmacological inhibition of TNF/TNFR targets of interest.* denotes P <0.05 in student t-test. Data from three unique stimulator-responder MLR pairs, mean ± SEM plotted. Large-molecule pharmacological TNF/TNFR inhibitors used: Adalimumab (abbr. Ada, α-TNF), Pateclizumab (α-LTA), Baminercept (abbr. Bam, LTβR decoy), Dapirolizumab (abbr. Dapiro, α-CD40L), Amlitelimab (abbr. Amlite, α-OX40L), CD30Li (α-CD30L), 4-1BB-Fc (4-1BB decoy), Quisovalimab (α-LIGHT), Duvakitug (α-TL1A), and GITRi (α-GITR).

Article Snippet: Adalimumab (Cat. HY-P9908), Pateclizumab (Cat. HY-P990034), Baminercept (Cat. HY-P99459), Amlitelimab (Cat. HY-P99434), Dapirolizumab (Cat. HY-P99842A), Quisovalimab (Cat. HY-P99810), Duvakitug (Cat. HY-P99842A), human IgG1 (Cat. HY-P99001) and human IgG4 (Cat. HY-P99003) were purchased from MedChemExpress.

Techniques: Inhibition, Control, Expressing

Journal: bioRxiv

Article Title: Combination antagonism of TNF superfamily signaling for T cell immunosuppression

doi: 10.64898/2026.04.27.721101

Figure Lengend Snippet: ( A-B ) Interleukin-2 (IL-2) and interferon gamma (IFN-γ) inhibition in CD3 + cells during allogeneic one-way MLR measured at day 2 and day 5, respectively, treated with 50 nM combination pharmacological inhibitors of TNF/TNFR targets of interest. Monotreatment groups included 50 nM of human IgG1. Cytokine expression normalized to IgG1 control treatment. * denotes P <0.05 in student t-test for monotreatments vs. IgG1 control. Data from three individual stimulator-responder MLR pairs, mean ± SEM plotted.

Article Snippet: Adalimumab (Cat. HY-P9908), Pateclizumab (Cat. HY-P990034), Baminercept (Cat. HY-P99459), Amlitelimab (Cat. HY-P99434), Dapirolizumab (Cat. HY-P99842A), Quisovalimab (Cat. HY-P99810), Duvakitug (Cat. HY-P99842A), human IgG1 (Cat. HY-P99001) and human IgG4 (Cat. HY-P99003) were purchased from MedChemExpress.

Techniques: Inhibition, Expressing, Control

Journal: NPJ Breast Cancer

Article Title: TGF-α/EGFR-mediated lymphatic metastasis reveals a repositionable therapeutic target in breast cancer

doi: 10.1038/s41523-026-00941-0

Figure Lengend Snippet: Studies were performed to analyze whether blockade of TGF-α could inhibit chemotactic invasion and lymphatic metastasis of 4T1-EGFR cells. a Results from transwell invasion assays showing that Fepixnebart, a neutralizing antibody against TGFα (aTGFα), significantly inhibited chemotactic invasion of 4T1-EGFR cells toward svLEC-conditioned media. An isotype matched IgG antibody was used as control. For each condition, three fields per well were imaged and quantified across three independent experiments based on crystal violet-stained areas. Statistical analysis was performed using an unpaired two-tailed Student’s T-test. b Schematic overview of the in vivo experimental setup. 4T1 cells were orthotopically implanted into mice, followed by tail vein injection of Fepixnebart. Tumor-draining lymph nodes were collected for analysis 10 days later. c Bar graphs showing quantification of CK⁺ tumor cells in inguinal (ILN) and axillary (ALN) lymph nodes 10 days after orthotopic injection of 4T1-EGFR cells into mammary fat pads. Mice received a single intravenous injection of Fepixnebart (10 mg/kg; n = 9) or isotype IgG control ( n = 8) at the time of tumor cell implantation. Data are shown as mean ± SEM; statistical analysis by unpaired two-tailed Student’s t-test.

Article Snippet: Simultaneously, mice received a single intravenous dose of Fepixnebart (10 mg/kg) or an isotype-matched human IgG4 control antibody (HY-P99003, MedChemExpress).

Techniques: Control, Staining, Two Tailed Test, In Vivo, Injection